Chatham Capital Group Inc. cut its stake in Pfizer Inc. (NYSE:PFE) by 6.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 27,643 shares of the biopharmaceutical company’s stock after selling 1,999 shares during the quarter. Chatham Capital Group Inc.’s holdings in Pfizer were worth $1,015,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds also recently made changes to their positions in the company. Apella Capital LLC grew its stake in shares of Pfizer by 3.4% in the third quarter. Apella Capital LLC now owns 14,255 shares of the biopharmaceutical company’s stock worth $523,000 after acquiring an additional 475 shares during the period. GW Henssler & Associates Ltd. grew its stake in shares of Pfizer by 13.8% in the third quarter. GW Henssler & Associates Ltd. now owns 256,450 shares of the biopharmaceutical company’s stock worth $9,412,000 after acquiring an additional 31,181 shares during the period. BHK Investment Advisors LLC grew its stake in shares of Pfizer by 4.7% in the third quarter. BHK Investment Advisors LLC now owns 9,420 shares of the biopharmaceutical company’s stock worth $346,000 after acquiring an additional 425 shares during the period. McCollum Christoferson Group LLC bought a new stake in shares of Pfizer in the third quarter worth approximately $217,000. Finally, First National Corp MA ADV grew its stake in shares of Pfizer by 4.6% in the third quarter. First National Corp MA ADV now owns 18,929 shares of the biopharmaceutical company’s stock worth $1,161,000 after acquiring an additional 841 shares during the period. Hedge funds and other institutional investors own 69.08% of the company’s stock.
PFE has been the subject of a number of research analyst reports. SVB Leerink lifted their price target on shares of Pfizer from $39.00 to $42.00 and gave the stock a “market perform” rating in a research note on Wednesday, July 29th. ValuEngine lowered shares of Pfizer from a “hold” rating to a “sell” rating in a research report on Thursday, July 30th. Truist initiated coverage on shares of Pfizer in a research report on Friday. They set a “buy” rating and a $42.00 target price for the company. Morgan Stanley boosted their target price on shares of Pfizer from $36.00 to $42.00 and gave the company an “equal weight” rating in a research report on Thursday, July 30th. Finally, Berenberg Bank initiated coverage on shares of Pfizer in a research report on Tuesday, September 29th. They set a “hold” rating and a $38.00 target price for the company. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and five have issued a buy rating to the stock. Pfizer has an average rating of “Hold” and a consensus price target of $39.81.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 28th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.64 by $0.14. Pfizer had a net margin of 28.80% and a return on equity of 25.11%. The firm had revenue of $11.80 billion for the quarter, compared to the consensus estimate of $11.55 billion. During the same quarter in the previous year, the firm earned $0.80 earnings per share. The company’s quarterly revenue was down 11.0% compared to the same quarter last year. On average, equities research analysts expect that Pfizer Inc. will post 2.84 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, November 6th will be issued a $0.38 dividend. This represents a $1.52 annualized dividend and a dividend yield of 3.98%. The ex-dividend date is Thursday, November 5th. Pfizer’s dividend payout ratio (DPR) is presently 51.53%.
In related news, Director Ronald E. Blaylock bought 13,000 shares of the stock in a transaction dated Thursday, August 6th. The shares were purchased at an average price of $38.55 per share, with a total value of $501,150.00. Following the completion of the acquisition, the director now owns 4,000 shares of the company’s stock, valued at $154,200. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 0.08% of the stock is currently owned by insiders.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Read More: Google Finance Portfolio Tips and Tricks
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.